MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 9, 2011, Pages 2405-2409

  Li, Ying ^a   Yan, Peng Wei ^a   Huang, Xin En ^a   Li, Cheng Guang ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Adjuvant chemotherapy; Clinical outcome; Gastric cancer; Genetic polymorphisms; Multi drug resistance

Indexed keywords

ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; STOMACH TUMOR; TREATMENT OUTCOME;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866279678     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ambdukar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol, 39, 361-98.
2. Brinkmann U, Eichelbaum M (2001). Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J, 1, 59-64.
3. Buda G, Maggini V, Galimberti S, et al. (2007). MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol, 137, 454-6.
4. Chang H, Rha SY, Jeung HC, et al. (2010). Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep, 23, 271-8.
5. Chen CJ, Chin JE, Ueda K, et al. (1986). Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47, 381-9.
6. Dean M, Rzhetsky A, Allikmets R (2001). The human ATP-binding cassette (ABC) transporter superfamily. Genome Res, 11, 1156-66.
7. Fromm MF (2002). The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev, 54, 1295-310.
8. Gerloff T, Schaefer M, Johne A, et al. (2002). MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol, 54, 610-6.
9. Hoffmeyer S, Burk O, von Richter O, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA, 97, 3473-8.
10. Illmer T, Schuler US, Thiede C, et al. (2002). MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemic patients. Cancer Res, 62, 4955-62.
11. Jamroziak K, Mlynarski W, Balcerczak E, et al. (2004). Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol, 72, 314-21.
12. Johnatty SE, Beesley J, Paul J, et al. (2008). ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res, 14, 5594-601.
13. Johne A, Köpke K, Gerloff T, et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther, 72, 584-94.
14. Juliano RL, Ling V (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455, 152-62.
15. Kim JP, Hur YS, Choe KJ, et al. (1993). Clinical analysis of 1136 early gastric cancers. Cancer Res Treat, 25, 808-18.
16. Leonessa F, Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer, 10, 43-73.
17. Macdonald JS (2004). Treatment of localized gastric cancer. Semin Oncol, 31, 566-73.
18. Marzolini C, Paus E, Buclin T, Kim RB (2004). Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther, 75, 13-33.
19. Nakamura T, Sakaeda T, Horinouchi M, et al. (2002). Effect of he mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther, 71, 297-303.
20. Pan JH, Han JX, Wu JM, et al. (2009). MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration, 78, 49-55.
21. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ (2008). MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration, 75, 380-5.
22. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
23. Salama NN, Yang Z, Bui T, Ho RJ (2006). MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci, 95, 2293-308.
24. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY (2006). MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol, 36, 137-41.
25. Stouch TR, Gudmundsson O (2002). Progress in understanding the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev, 54, 315-28.
26. Terek MC, Zekioglu O, Sendag F, Akercan F, et al. (2003). MDR1 gene expression in endometrial carcinoma. Int J Gynecol. Cancer, 13, 673-7.